Objective:To investigate the protective function of tocilizumab in human cardiac myocytes ischemia-reperfusion injury.Methods:The human cardiac myocytes were treated by tocilizumab with different concentrations(1.0 mg...Objective:To investigate the protective function of tocilizumab in human cardiac myocytes ischemia-reperfusion injury.Methods:The human cardiac myocytes were treated by tocilizumab with different concentrations(1.0 mg/mL,3.0 mg/mL,5.0 mg/mL) for 24 h.then cells were cultured in ischemia environment for 24 h and reperfusion environment for 1 h.The MTT and flow cytometry were used to detect the proliferation and apoptosis of human cardiac myocytes,respectively.The mRNA and protein expressions of Bcl-2 and Bax were measured by qRT-PCR and western blot,respectively.Results:Compared to the negative group,pretreated by tocilizumab could significantly enhance the proliferation viability and suppress apoptosis of human cardiac myocytes after suffering ischemia reperfusion injury(P<0.05).The expression of Bcl-2 in tocilizumab treated group were higher than NC group(P<0.05).while the Bax expression were lower(P<0.05).Conclusions:Tocilizumab could significantly inhibit apoptosis and keep the proliferation viability of human cardiac myocytes after suffering ischemia reperfusion injury.Tocilizumab may obtain a widely application in the protection of ischemia reperfusion injury.展开更多
Background：Since 2010,two versions of National Guidelines aimed at promoting the management of ST-segment elevation myocardial infarction （STEMI） have been formulated by the Chinese Society of Cardiology.However,li...Background：Since 2010,two versions of National Guidelines aimed at promoting the management of ST-segment elevation myocardial infarction （STEMI） have been formulated by the Chinese Society of Cardiology.However,little is known about the changes in clinical characteristics,management,and in-hospital outcomes in rural areas.Methods：In the present multicenter,cross-sectional study,participants were enrolled from rural hospitals located in Liaoning province in Northeast China,during two different periods （from June 2009 to June 2010 and from January 2015 to December 2015）.Data collection was conducted using a standardized questionnaire.In total,607 and 637 STEMI patients were recruited in the 2010 and 2015 cohorts,respectively.Results：STEMI patients in rural hospitals were older in the second group （63 years vs.65 years,P =0.039）.We found increases in the prevalence of hypertension,prior percutaneous coronary intervention （PCI）,and prior stroke.Over the past 5 years,the cost during hospitalization almost doubled.The proportion of STEMI patients who underwent emergency reperfusion had significantly increased from 42.34% to 54.47% （P 〈 0.0001）.Concurrently,the proportion of primary PCI increased from 3.62% to 10.52% （P 〈 0.0001）.The past 5 years have also seen marked increases in the use of guideline-recommended drugs and clinical examinations.However,in-hospital mortality and major adverse cardiac events did not significantly change over time （13.01% vs.10.20%,P =0.121;13.34% vs.13.66%,P =0.872）.Conclusions：Despite the great progress that has been made in guideline-recommended therapies,in-hospital outcomes among rural STEMI patients have not significantly improved.Therefore,there is still substantial room for improvement in the quality of care.展开更多
基金supported by a grant from the Health Department Foundation of Zhejiang Province(2010KYA102)
文摘Objective:To investigate the protective function of tocilizumab in human cardiac myocytes ischemia-reperfusion injury.Methods:The human cardiac myocytes were treated by tocilizumab with different concentrations(1.0 mg/mL,3.0 mg/mL,5.0 mg/mL) for 24 h.then cells were cultured in ischemia environment for 24 h and reperfusion environment for 1 h.The MTT and flow cytometry were used to detect the proliferation and apoptosis of human cardiac myocytes,respectively.The mRNA and protein expressions of Bcl-2 and Bax were measured by qRT-PCR and western blot,respectively.Results:Compared to the negative group,pretreated by tocilizumab could significantly enhance the proliferation viability and suppress apoptosis of human cardiac myocytes after suffering ischemia reperfusion injury(P<0.05).The expression of Bcl-2 in tocilizumab treated group were higher than NC group(P<0.05).while the Bax expression were lower(P<0.05).Conclusions:Tocilizumab could significantly inhibit apoptosis and keep the proliferation viability of human cardiac myocytes after suffering ischemia reperfusion injury.Tocilizumab may obtain a widely application in the protection of ischemia reperfusion injury.
文摘Background：Since 2010,two versions of National Guidelines aimed at promoting the management of ST-segment elevation myocardial infarction （STEMI） have been formulated by the Chinese Society of Cardiology.However,little is known about the changes in clinical characteristics,management,and in-hospital outcomes in rural areas.Methods：In the present multicenter,cross-sectional study,participants were enrolled from rural hospitals located in Liaoning province in Northeast China,during two different periods （from June 2009 to June 2010 and from January 2015 to December 2015）.Data collection was conducted using a standardized questionnaire.In total,607 and 637 STEMI patients were recruited in the 2010 and 2015 cohorts,respectively.Results：STEMI patients in rural hospitals were older in the second group （63 years vs.65 years,P =0.039）.We found increases in the prevalence of hypertension,prior percutaneous coronary intervention （PCI）,and prior stroke.Over the past 5 years,the cost during hospitalization almost doubled.The proportion of STEMI patients who underwent emergency reperfusion had significantly increased from 42.34% to 54.47% （P 〈 0.0001）.Concurrently,the proportion of primary PCI increased from 3.62% to 10.52% （P 〈 0.0001）.The past 5 years have also seen marked increases in the use of guideline-recommended drugs and clinical examinations.However,in-hospital mortality and major adverse cardiac events did not significantly change over time （13.01% vs.10.20%,P =0.121;13.34% vs.13.66%,P =0.872）.Conclusions：Despite the great progress that has been made in guideline-recommended therapies,in-hospital outcomes among rural STEMI patients have not significantly improved.Therefore,there is still substantial room for improvement in the quality of care.
